NCT00059813View on ClinicalTrials.gov

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

June 30, 2005

Conditions
Recurrent Renal Cell CancerStage IV Renal Cell Cancer
Interventions
BIOLOGICAL

recombinant interferon alfa

Given SC

BIOLOGICAL

oblimersen sodium

Given IV

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

91010

City of Hope, Duarte

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00059813 - Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer | Biotech Hunter | Biotech Hunter